We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva has filed a motion in district court seeking a trial postponement while an interim appeal is ongoing, the latest in a back-and-forth with the Department of Justice (DOJ) which has accused the Israeli drugmaker of defrauding Medicare via a Copaxone (glatiramer) kickback scheme involving charitable foundations. Read More
Seven major pharmaceutical companies — AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda — have formed the INTREPID (International Readiness for Preventing Infectious Viral Disease) Alliance to accelerate progress in discovery and development of new antivirals for future pandemics. Read More
A vaccine for a common — but deadly — infection of newborns, a new cancer treatment, and more promising data on an Alzheimer’s drug are among the stories we cover this month. Read More
The FDA has issued a final guidance outlining a program that allows stakeholders to propose pharmaceutical quality standards for recognition by CDER, providing industry with additional resources for pharmaceutical development and manufacturing. Read More
The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and economic value of Novartis’s drug iptacopan for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare genetic blood disease. Read More
Upcoming events in the coming weeks include six FDA advisory committee meetings as well as the GMP Quality Management vSummit, and webinars from FDAnews, a WCG company on reliability assessment and medical device risk management tools. Read More
Pfizer said that crews are working around the clock to restore power, assess the structural integrity of the building and move finished medicines to nearby sites for storage. Read More
Drug-device combination products can pose cumbersome regulatory challenges for companies, say regulatory experts, primarily because the product has to comply with two complicated regulatory systems that are not designed to work together. Read More
Recalls can be messy, complicated matters, especially for manufacturers that don’t have a plan in place for analyzing a problem, determining a course of action and carrying out all recall-related tasks in compliance with FDA requirements. Read More
The FDA has issued final guidance on assessment and control of DNA reactive impurities in harmony with guidance prepared by the International Council for Harmonisation (ICH). Read More
Astellas Pharma announced a $21.3 million research collaboration with PeptiDream to discover novel protein degraders — enzymes that disassemble and break down unneeded proteins — used in cancer treatments. Read More